Indian Court Allows Dr. Reddy's to Produce Generic Versions of Novo Nordisk's Blockbuster Drugs

Dow Jones2025-12-04

By Dominic Chopping

An Indian court allowed Dr. Reddy's Laboratories to manufacture and export generic versions of Novo Nordisk's blockbuster diabetes and weight-loss drugs.

In a Dec. 2 decision, the Delhi High Court dismissed Novo Nordisk's application to block production of semaglutide--the key ingredient in Ozempic and Wegovy--allowing the Indian drugmaker to make the drug and export it to countries where it doesn't have patent protection.

The decision comes as the patent for semaglutide is due to expire in India early next year.

According to court documents, Dr. Reddy's confirmed that it wouldn't sell the drug in India until the patent expires next March, and the court ordered the company to keep a record of the quantity and value of the products its manufactures and sells.

Dr. Reddy's began producing the drug in April this year, according to the documents.

Patent protections for semaglutide expire in India, Canada, Brazil and China next year, clearing the way for cheaper generic versions to be sold in those markets. In Europe, the U.S. and Japan, patents aren't due to expire until the 2030s.

Novo Nordisk has the option to appeal to the Supreme Court.

Novo Nordisk and Dr. Reddy's didn't respond to requests for comment.

Write to Dominic Chopping at dominic.chopping@wsj.com

(END) Dow Jones Newswires

December 04, 2025 05:27 ET (10:27 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588888079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 18:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588888079","market":"sh","top_or_hot":-1,"title":"Indian Court Allows Dr. Reddy's to Produce Generic Versions of Novo Nordisk's Blockbuster Drugs","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dominic Chopping \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  An Indian court allowed Dr. Reddy's Laboratories to manufacture and export generic versions of <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s blockbuster diabetes and weight-loss drugs. \n</p>\n<p>\n  In a Dec. 2 decision, the Delhi High Court dismissed Novo Nordisk's application to block production of semaglutide--the key ingredient in Ozempic and Wegovy--allowing the Indian drugmaker to make the drug and export it to countries where it doesn't have patent protection. \n</p>\n<p>\n  The decision comes as the patent for semaglutide is due to expire in India early next year. \n</p>\n<p>\n  According to court documents, Dr. Reddy's confirmed that it wouldn't sell the drug in India until the patent expires next March, and the court ordered the company to keep a record of the quantity and value of the products its manufactures and sells. \n</p>\n<p>\n  Dr. Reddy's began producing the drug in April this year, according to the documents. \n</p>\n<p>\n  Patent protections for semaglutide expire in India, Canada, Brazil and China next year, clearing the way for cheaper generic versions to be sold in those markets. In Europe, the U.S. and Japan, patents aren't due to expire until the 2030s. \n</p>\n<p>\n  Novo Nordisk has the option to appeal to the Supreme Court. \n</p>\n<p>\n  Novo Nordisk and Dr. Reddy's didn't respond to requests for comment. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dominic Chopping at dominic.chopping@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 04, 2025 05:27 ET (10:27 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Indian Court Allows Dr. Reddy's to Produce Generic Versions of Novo Nordisk's Blockbuster Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndian Court Allows Dr. Reddy's to Produce Generic Versions of Novo Nordisk's Blockbuster Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-04 18:27</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dominic Chopping \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  An Indian court allowed Dr. Reddy's Laboratories to manufacture and export generic versions of <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s blockbuster diabetes and weight-loss drugs. \n</p>\n<p>\n  In a Dec. 2 decision, the Delhi High Court dismissed Novo Nordisk's application to block production of semaglutide--the key ingredient in Ozempic and Wegovy--allowing the Indian drugmaker to make the drug and export it to countries where it doesn't have patent protection. \n</p>\n<p>\n  The decision comes as the patent for semaglutide is due to expire in India early next year. \n</p>\n<p>\n  According to court documents, Dr. Reddy's confirmed that it wouldn't sell the drug in India until the patent expires next March, and the court ordered the company to keep a record of the quantity and value of the products its manufactures and sells. \n</p>\n<p>\n  Dr. Reddy's began producing the drug in April this year, according to the documents. \n</p>\n<p>\n  Patent protections for semaglutide expire in India, Canada, Brazil and China next year, clearing the way for cheaper generic versions to be sold in those markets. In Europe, the U.S. and Japan, patents aren't due to expire until the 2030s. \n</p>\n<p>\n  Novo Nordisk has the option to appeal to the Supreme Court. \n</p>\n<p>\n  Novo Nordisk and Dr. Reddy's didn't respond to requests for comment. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dominic Chopping at dominic.chopping@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 04, 2025 05:27 ET (10:27 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756168.USD","symbol_name":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2588888079","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588888079","pubTimestamp":1764844020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"An Indian court allowed Dr. Reddy's Laboratories to manufacture and export generic versions of Novo Nordisk's blockbuster diabetes and weight-loss drugs.In a Dec. 2 decision, the Delhi High Court dismissed Novo Nordisk's application to block production of semaglutide--the key ingredient in Ozempic and Wegovy--allowing the Indian drugmaker to make the drug and export it to countries where it doesn't have patent protection.The decision comes as the patent for semaglutide is due to expire in India early next year.According to court documents, Dr. Reddy's confirmed that it wouldn't sell the drug in India until the patent expires next March, and the court ordered the company to keep a record of the quantity and value of the products its manufactures and sells.Dr. Reddy's began producing the drug in April this year, according to the documents.Patent protections for semaglutide expire in India, Canada, Brazil and China next year, clearing the way for cheaper generic versions to be sold in tho","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4588":"碎股","RDY":"如瑞迪博士","BK4523":"印度概念","BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4557":"大麻股","NVO":"诺和诺德","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4532":"文艺复兴科技持仓","BK4596":"哈里斯概念","BK4599":"减肥药","LU0348744763.USD":"ALLIANZ ASIA PACIFIC INCOME \"A\" (USD) INC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4007":"制药"},"translate_title":"印度法院允许Dr.Reddy's生产诺和诺德重磅药物的仿制药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.5,"RDY":0.9},"content_text":"By Dominic Chopping \n\n\n \n\n\n  An Indian court allowed Dr. Reddy's Laboratories to manufacture and export generic versions of Novo Nordisk's blockbuster diabetes and weight-loss drugs. \n\n\n  In a Dec. 2 decision, the Delhi High Court dismissed Novo Nordisk's application to block production of semaglutide--the key ingredient in Ozempic and Wegovy--allowing the Indian drugmaker to make the drug and export it to countries where it doesn't have patent protection. \n\n\n  The decision comes as the patent for semaglutide is due to expire in India early next year. \n\n\n  According to court documents, Dr. Reddy's confirmed that it wouldn't sell the drug in India until the patent expires next March, and the court ordered the company to keep a record of the quantity and value of the products its manufactures and sells. \n\n\n  Dr. Reddy's began producing the drug in April this year, according to the documents. \n\n\n  Patent protections for semaglutide expire in India, Canada, Brazil and China next year, clearing the way for cheaper generic versions to be sold in those markets. In Europe, the U.S. and Japan, patents aren't due to expire until the 2030s. \n\n\n  Novo Nordisk has the option to appeal to the Supreme Court. \n\n\n  Novo Nordisk and Dr. Reddy's didn't respond to requests for comment. \n\n\n \n\n\n  Write to Dominic Chopping at dominic.chopping@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 04, 2025 05:27 ET (10:27 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588888079","isCrawlerRequest":true}